Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-Origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 3 to 17 Years.
Latest Information Update: 07 Feb 2014
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sanofi Pasteur
- 15 Apr 2011 Status changed from recruiting to completed as reported by ClnicalTrials.gov.
- 29 Sep 2010 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
- 27 Oct 2009 Interim results reported in a Sanofi Pasteur media release.